Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$87.47
-0.3%		$85.16
$54.11
▼
$92.59
$33.79B1.423.97 million shs2.14 million shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$513.39
-1.7%		$547.06
$500.61
▼
$769.98
$41.08B1.54492,158 shs328,284 shs
ResMed Inc. stock logo
RMD
ResMed
$222.12
-0.1%		$220.90
$180.26
▼
$284.87
$32.02B0.771.32 million shs788,841 shs
Demant A/S Unsponsored ADR stock logo
WILYY
Demant A/S
$23.85
$22.28
$13.45
▼
$23.85
$10.10B1.2365 shs98 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
-2.01%+0.45%-3.66%+27.79%+28.64%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
+0.10%+1.64%-6.70%-5.93%-19.49%
ResMed Inc. stock logo
RMD
ResMed
-0.37%-2.74%-4.55%+11.85%-19.47%
Demant A/S Unsponsored ADR stock logo
WILYY
Demant A/S
0.00%0.00%+3.70%+23.90%+28.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$87.47
-0.3%		$85.16
$54.11
▼
$92.59
$33.79B1.423.97 million shs2.14 million shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$513.39
-1.7%		$547.06
$500.61
▼
$769.98
$41.08B1.54492,158 shs328,284 shs
ResMed Inc. stock logo
RMD
ResMed
$222.12
-0.1%		$220.90
$180.26
▼
$284.87
$32.02B0.771.32 million shs788,841 shs
Demant A/S Unsponsored ADR stock logo
WILYY
Demant A/S
$23.85
$22.28
$13.45
▼
$23.85
$10.10B1.2365 shs98 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
-2.01%+0.45%-3.66%+27.79%+28.64%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
+0.10%+1.64%-6.70%-5.93%-19.49%
ResMed Inc. stock logo
RMD
ResMed
-0.37%-2.74%-4.55%+11.85%-19.47%
Demant A/S Unsponsored ADR stock logo
WILYY
Demant A/S
0.00%0.00%+3.70%+23.90%+28.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.92
Moderate Buy$89.081.84% Upside
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.60
Moderate Buy$747.0045.50% Upside
ResMed Inc. stock logo
RMD
ResMed
2.44
Hold$241.698.81% Upside
Demant A/S Unsponsored ADR stock logo
WILYY
Demant A/S
2.60
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest WILYY, IDXX, DXCM, and RMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/18/2026
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$93.00 ➝ $102.00
9/18/2026
DexCom, Inc. stock logo
DXCM
DexCom
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$95.00
9/15/2026
ResMed Inc. stock logo
RMD
ResMed
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSector Perform ➝ Outperform$244.00 ➝ $262.00
9/10/2026
ResMed Inc. stock logo
RMD
ResMed
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
8/31/2026
ResMed Inc. stock logo
RMD
ResMed
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$255.00 ➝ $267.00
8/27/2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C+) ➝ Hold (C)
8/19/2026
ResMed Inc. stock logo
RMD
ResMed
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$230.00
8/19/2026
ResMed Inc. stock logo
RMD
ResMed
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$230.00
8/11/2026
DexCom, Inc. stock logo
DXCM
DexCom
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/11/2026
ResMed Inc. stock logo
RMD
ResMed
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/11/2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$800.00 ➝ $710.00
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.66B7.08$2.71 per share32.33$7.04 per share12.42
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$4.30B9.40$14.85 per share34.57$20.10 per share25.54
ResMed Inc. stock logo
RMD
ResMed
$5.65B5.67$12.94 per share17.16$45.40 per share4.89
Demant A/S Unsponsored ADR stock logo
WILYY
Demant A/S
$3.48B2.90$0.88 per share27.13$3.51 per share6.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.5334.5728.401.5020.12%35.94%14.75%10/29/2026 (Estimated)
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$1.06B$14.2236.1030.892.7825.03%71.96%33.60%11/2/2026 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.52B$10.4321.3016.931.4026.94%25.58%18.89%10/29/2026 (Estimated)
Demant A/S Unsponsored ADR stock logo
WILYY
Demant A/S
$233.91MN/AN/A19.88N/AN/AN/AN/AN/A

Latest WILYY, IDXX, DXCM, and RMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q4 2026
ResMed Inc. stock logo
RMD
ResMed
$2.89$2.95+$0.06$2.64$1.46 billion$1.46 billion
8/4/2026Q2 2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.94$4.27+$0.33$4.27$1.20 billion$1.22 billion
7/30/2026Q2 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.6110$0.70+$0.0890$0.64$1.29 billion$1.31 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$2.641.19%+9.00%25.31%13 Years
Demant A/S Unsponsored ADR stock logo
WILYY
Demant A/S
N/AN/AN/AN/AN/A

Latest WILYY, IDXX, DXCM, and RMD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2026
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.661.15%8/20/20268/20/20269/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.47
1.73
1.43
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.19
1.17
0.87
ResMed Inc. stock logo
RMD
ResMed
0.06
3.10
2.42
Demant A/S Unsponsored ADR stock logo
WILYY
Demant A/S
1.65
1.36
1.00

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%
ResMed Inc. stock logo
RMD
ResMed
54.98%
Demant A/S Unsponsored ADR stock logo
WILYY
Demant A/S
N/A

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.79%
ResMed Inc. stock logo
RMD
ResMed
0.65%
Demant A/S Unsponsored ADR stock logo
WILYY
Demant A/S
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000377.36 million376.30 millionOptionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11,00078.78 million78.16 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
11,370144.25 million143.31 millionOptionable
Demant A/S Unsponsored ADR stock logo
WILYY
Demant A/S
26,704423.51 millionN/ANot Optionable

Recent News About These Companies

Jyske Bank downgrades Demant A to hold from buy
September 24 at 10:27 AM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/jyske-bank-downgrades-demant-a-to-hold-from-buy/ar-AA2cSb8F
Cours Demant A/S Deutsche Boerse AG
September 23 at 12:16 AM  |  zonebourse.comZ
Demant stock gains as Jefferies keeps a 345 DKK target
September 23 at 9:12 AM  |  ad-hoc-news.deA
Demant stock trades near DKK 160 after Copenhagen market data
September 22 at 9:34 AM  |  ad-hoc-news.deA
Demant stock holds near 52-week high as investors weigh first-half performance
September 21 at 8:58 AM  |  ad-hoc-news.deA
Demant stock heads into the open after a recent Copenhagen gain
September 21 at 3:58 AM  |  ad-hoc-news.deA
Demant stock gains as investors digest solid first-half figures
September 20, 2026  |  ad-hoc-news.deA
Demant stock gains as analysts highlight valuation after strong first-half figures
September 20, 2026  |  ad-hoc-news.deA
Demant stock gains as Oddo raises price target to 275 DKK
September 18, 2026  |  ad-hoc-news.deA
Demant stock heads into the open after a modest gain
September 9, 2026  |  ad-hoc-news.deA
Demant A/S (WILYY) Q2 2026 Earnings Call Transcript
August 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4935684-demant-a-s-wilyy-q2-2026-earnings-call-transcript
Demant A/S: Demant-owned Oticon announces launch of new flagship hearing aids
August 12, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69279299-demant-a-s-demant-owned-oticon-announces-launch-of-new-flagship-hearing-aids-399.htm
Demant AS ADR WILYY
August 7, 2026  |  morningstar.comM
Demant A/S : Jyske Bank n'est plus positif
August 6, 2026  |  zonebourse.comZ
Demant’s Latest AI Hearing Aid Fuels Best Quarter in 26 Years
June 26, 2026  |  bloomberg.comhttps://www.bloomberg.com/news/articles/2026-06-26/demant-s-latest-ai-hearing-aid-fuels-best-quarter-in-26-years
Demant shares surge 15% after Oticon Zeal drives Q1 growth
May 7, 2026  |  za.investing.comhttps://za.investing.com/news/earnings/demant-shares-surge-15-after-oticon-zeal-drives-q1-growth-4255401
Demant A/S: Expansion of Demant's Executive Leadership Team
May 6, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68411363-demant-a-s-expansion-of-demant-s-executive-leadership-team-399.htm
Jefferies flips on hearing aid giants, upgrades Demant, cuts Sonova
March 18, 2026  |  investing.comhttps://www.investing.com/news/stock-market-news/jefferies-flips-on-hearing-aid-giants-upgrades-demant-cuts-sonova-4568271
3 European Stocks Estimated To Be Trading At Over 49.3% Below Intrinsic Value
February 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/3-european-stocks-estimated-trading-053811649.html
Demant tops Q4 forecasts on Diagnostics recovery, but shares tumble on outlook
February 4, 2026  |  investing.comhttps://www.investing.com/news/earnings/demant-tops-q4-forecasts-on-diagnostics-recovery-flags-subdued-2026-outlook-4480698

New MarketBeat Followers Over Time

Media Sentiment Over Time

DexCom stock logo

DexCom NASDAQ:DXCM

$87.47 -0.26 (-0.30%)
Closing price 04:00 PM Eastern
Extended Trading
$87.19 -0.28 (-0.32%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$513.39 -8.63 (-1.65%)
Closing price 04:00 PM Eastern
Extended Trading
$512.72 -0.66 (-0.13%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

ResMed stock logo

ResMed NYSE:RMD

$222.12 -0.18 (-0.08%)
Closing price 03:59 PM Eastern
Extended Trading
$222.86 +0.75 (+0.34%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Demant A/S stock logo

Demant A/S OTCMKTS:WILYY

$23.85 0.00 (0.00%)
As of 09/23/2026

Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services. The Communications segment provides headsets and solutions for the professional call centers, office markets, and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas